Who is eligible for clinical trial NCT05762952?

Participants must meet the protocol's inclusion criteria for Myocardial Ischemia. The stated age range is 18 Years to 99 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05762952 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-08-18

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease (NCT05762952)

A Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate Microvascular Disease After 12 Weeks of Therapy With Sodium-glucose Co-transporter 2 Inhibitor Compared to Placebo in Symptomatic Women With Non-obstructive Coronary Artery Disease

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: University of Virginia

🩺 Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to test the effects of a drug (in the drug class called sodium-glucose cotransporter 2 inhibitors) in women who have symptoms of ischemic heart disease. The main questions the study aims to answer are: Does blood flow in the heart improve with study drug? Participants will be randomly assigned to a 12-week course of the study drug, dapagliflozin 10mg, or placebo. Blood flow in the heart will be assessed using stress cardiac magnetic resonance imaging at baseline and 12 weeks. The researchers will compare the results from the two groups.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (14 items).

Location: University of Virginia — Charlottesville, Virginia

Age range: 18 Years to 99 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Willing to provide written informed consent.
Signs and symptoms of suspected ischemia that prompted referral for further evaluation by cardiac catheterization or coronary computed tomography within two years of consent.
No evidence of obstructive epicardial coronary artery disease (stenosis \>50%) of a major epicardial vessel (\>3mm) or a fractional flow reserve \>0.80 by invasive catheterization or coronary computed tomography. (Participants who have not undergone cardiac catheterization or coronary angiogram within the last 2 years for their clinical care will be screened with computed angiogram of the coronary arteries to confirm eligibility).
Estimated glomerular filtration rate ≥30ml/min/1.73m2 at enrollment
For subjects having a history of type 2 diabetes mellitus: approval of diabetes care/prescribing provider

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
History of non-ischemic cardiomyopathy with left ventricular ejection fraction \<40% or hypertrophic cardiomyopathy.
History of congestive heart failure, severe pulmonary disease, liver disease
History of Acute coronary syndrome within previous 30 days
Stroke within the last 180 days or intracranial hemorrhage at any time.
Severe Valvular disease
Life expectancy \<3 years, due to non-cardiovascular comorbidity.
Pregnancy or women who are breast-feeding
Type 1 diabetes mellitus
History of diabetic ketoacidosis in subjects with Type 2 Diabetes Mellitus
Symptomatic hypotension or systolic blood pressure \<95 mmHg on 2 consecutive measurements
Active malignancy requiring treatment at the time of visit

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Virginia — Charlottesville, Virginia

📞 Contact the Study Coordinator

Phone: (434) 924-6104

Email: clf4w@uvahealth.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myocardial Ischemia

Bright Light Exposure in Surgical Patients — Denver, Colorado
Ischaemic PReconditioning In Non Cardiac surgEry — Xi'an,

Explore by condition: All Myocardial Ischemia clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗